Clinical Trials
51 trialsNCT02379416 2026-06-01
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04449549 2026-05-22
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03768063 2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05112965 2026-04-06
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT01374620 2026-03-16
PAL-ANGI2
Centre Oscar Lambret
Phase 1 Completed
NCT03564691 2025-10-07
MK-4830-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03918278 2025-06-25
MK-0482-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT06904300 2025-06-05
Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT03873883 2024-09-19
IO-001
iTeos Therapeutics
Phase 1 Completed
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02761694 2023-05-06
MK-4440-001
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT05467189 2022-07-20
Antineoplastic Drugs in Elderly Patients
Shandong University
Recruiting
NCT02630199 2022-06-15
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer
Samsung Medical Center
Phase 1 Completed
NCT05241132 2022-02-15
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT01362374 2022-01-12
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01968915 2020-12-19
Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01285466 2020-12-09
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
Phase 1 Completed
NCT01633970 2020-10-08
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01653470 2020-01-28
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03057366 2019-11-18
A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT00848718 2019-11-12
MK-2206-003
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01868022 2019-08-19
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
GlaxoSmithKline
Phase 1 Completed
NCT01938846 2019-01-04
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT01653912 2018-04-02
Dose-finding Study in Platinum-Resistant Ovarian Cancer
Accenture
Phase 1/2 Completed
NCT01411410 2017-10-11
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
Bayer
Phase 1 Completed
NCT02240212 2017-04-11
Study of Afuresertib Combined With Paclitaxel in Gastric Cancer
Novartis
Phase 1 Completed
NCT00607048 2017-03-27
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT00811993 2016-11-02
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT01497470 2016-10-10
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
Achieve Life Sciences
Phase 1 Completed
NCT00201734 2016-09-23
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
Ohio State University Comprehensive Cancer Center
Phase 1/2 Terminated
NCT00422682 2016-06-10
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT01110603 2016-05-05
A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)
Tesaro, Inc.
Phase 1 Terminated
NCT00809133 2016-03-14
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT01579578 2014-09-12
Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer
AstraZeneca
Phase 2 Terminated
NCT01235897 2014-04-17
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
University of California, San Francisco
Phase 1 Completed
NCT00399126 2014-02-13
Phase I Trial of Paclitaxel With Perifosine
AEterna Zentaris
Phase 1 Completed
NCT01031212 2013-05-13
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
University of California, San Francisco
Phase 1 Withdrawn
NCT00972205 2012-07-19
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase NA Completed
NCT00793897 2012-07-13
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT01204996 2012-05-30
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
Centocor, Inc.
Phase 1 Completed
NCT00454649 2012-04-04
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Pfizer
Phase 1 Completed
NCT00113438 2011-11-01
Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
Mateon Therapeutics
Phase 2 Completed
NCT00100139 2011-07-04
Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer
INSYS Therapeutics Inc
Phase 1 Completed
NCT00496028 2010-09-22
Phase I Study in Patients With Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00511849 2010-02-17
Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00606515 2009-02-10
LPS-PK-H
Shandong Luye Pharmaceutical Co., Ltd.
Phase 4 Completed